Literature DB >> 25827266

Carotid blowout syndrome in pharyngeal cancer patients treated by hypofractionated stereotactic re-irradiation using CyberKnife: A multi-institutional matched-cohort analysis.

Hideya Yamazaki1, Mikio Ogita2, Kengo Himei3, Satoaki Nakamura4, Tadayuki Kotsuma5, Ken Yoshida5, Yasuo Yoshioka6.   

Abstract

BACKGROUND AND
PURPOSE: Although reirradiation has attracted attention as a potential therapy for recurrent head and neck tumors with the advent of modern radiotherapy, severe rate toxicity such as carotid blowout syndrome (CBOS) limits its potential. The aim of this study was to identify the risk factors of CBOS after hypofractionated stereotactic radiotherapy (SBRT). METHODS AND PATIENTS: We conducted a matched-pair design examination of pharyngeal cancer patients treated by CyberKnife reirradiation in four institutes. Twelve cases with CBOS were observed per 60 cases without CBOS cases. Prognostic factors for CBOS were analyzed and a risk classification model was constructed.
RESULTS: The median prescribed radiation dose was 30 Gy in 5 fractions with CyberKnife SBRT after 60 Gy/30 fractions of previous radiotherapy. The median duration between reirradiation and CBOS onset was 5 months (range, 0-69 months). CBOS cases showed a median survival time of 5.5 months compared to 22.8 months for non-CBOS cases (1-year survival rate, 36% vs.72%; p=0.003). Univariate analysis identified an angle of carotid invasion of >180°, the presence of ulceration, planning treatment volume, and irradiation to lymph node areas as statistically significant predisposing factors for CBOS. Only patients with carotid invasion of >180° developed CBOS (12/50, 24%), whereas no patient with tumor involvement less than a half semicircle around the carotid artery developed CBOS (0/22, 0%, p=0.03). Multivariate Cox hazard model analysis revealed that the presence of ulceration and irradiation to lymph nodes were statistically significant predisposing factors. Thus, we constructed a CBOS risk classification system: CBOS index=(summation of risk factors; carotid invasion >180°, presence of ulceration, lymph node area irradiation). This system sufficiently separated the risk groups.
CONCLUSION: The presence of ulceration and lymph node irradiation are risk factors of CBOS. The CBOS index, including carotid invasion of >180°, is useful in classifying the risk factors and determining the indications for reirradiation.
Copyright © 2015. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Carotid blow-out syndrome; CyberKnife; Head neck cancer; Reirradiation; Stereotactic radiotherapy

Mesh:

Year:  2015        PMID: 25827266     DOI: 10.1016/j.radonc.2015.02.021

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  17 in total

1.  Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma.

Authors:  Victor H F Lee; Dora L W Kwong; To-Wai Leung; Sherry C Y Ng; Ka-On Lam; Chi-Chung Tong; Chun-Kin Sze
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-10-13       Impact factor: 2.503

2.  Reirradiation for recurrent head and neck cancers using charged particle or photon radiotherapy.

Authors:  Hideya Yamazaki; Yusuke Demizu; Tomoaki Okimoto; Mikio Ogita; Kengo Himei; Satoaki Nakamura; Gen Suzuki; Ken Yoshida; Tadayuki Kotsuma; Yasuo Yoshioka; Ryoongjin Oh
Journal:  Strahlenther Onkol       Date:  2017-04-19       Impact factor: 3.621

3.  Dose-response modeling the risk of carotid bleeding events after stereotactic body radiation therapy for previously irradiated head and neck cancer.

Authors:  Diane C Ling; John A Vargo; Brian J Gebhardt; Rachel J Grimm; David A Clump; Robert L Ferris; James P Ohr; Dwight E Heron
Journal:  J Radiosurg SBRT       Date:  2019

4.  Predictive value of skin invasion in recurrent head and neck cancer patients treated by hypofractionated stereotactic re-irradiation using a cyberknife.

Authors:  Hideya Yamazaki; Mikio Ogita; Kengo Himei; Satoaki Nakamura; Gen Suzuki; Tadayuki Kotsuma; Ken Yoshida; Yasuo Yoshioka
Journal:  Radiat Oncol       Date:  2015-10-15       Impact factor: 3.481

5.  Reirradiation using robotic image-guided stereotactic radiotherapy of recurrent head and neck cancer.

Authors:  Hideya Yamazaki; Mikio Ogita; Kengo Himei; Satoaki Nakamura; Gen Suzuki; Ken Yoshida; Tadayuki Kotsuma; Yasuo Yoshioka
Journal:  J Radiat Res       Date:  2016-03-16       Impact factor: 2.724

6.  Effect of intratumoral abscess/necrosis on the outcome for head and neck cancer patients treated by hypofractionated stereotactic re-irradiation using CyberKnife®.

Authors:  Hideya Yamazaki; Mikio Ogita; Kengo Himei; Satoaki Nakamura; Gen Suzuki; Tadayuki Kotsuma; Ken Yoshida; Yasuo Yoshioka
Journal:  Mol Clin Oncol       Date:  2017-07-24

7.  A surveillance study of the current status of reirradiation and patterns of practice.

Authors:  Hideya Yamazaki; Masato Fushiki; Takashi Mizowaki
Journal:  J Radiat Res       Date:  2016-09-08       Impact factor: 2.724

8.  Usefulness of Stereotactic Radiotherapy Using CyberKnife for Recurrent Lymph Node Metastasis of Differentiated Thyroid Cancer.

Authors:  Joji Kawabe; Shigeaki Higashiyama; Mitsuharu Sougawa; Atsushi Yoshida; Kohei Kotani; Susumu Shiomi
Journal:  Case Rep Endocrinol       Date:  2017-03-15

9.  A systematic review and practical considerations of stereotactic body radiotherapy in the treatment of head and neck cancer.

Authors:  Muhammad Shahid Iqbal; Nick West; Neil Richmond; Josef Kovarik; Isabel Gray; Nick Willis; David Morgan; Gozde Yazici; Mustafa Cengiz; Vinidh Paleri; Charles Kelly
Journal:  Br J Radiol       Date:  2020-09-24       Impact factor: 3.039

10.  Prevention and early management of carotid blowout syndrome for patients receiving head and neck salvage boron neutron capture therapy (BNCT).

Authors:  Tien-Li Lan; Feng-Chi Chang; Chun-Wei Wang; Kazuyo Igawa; Szu-Hsien Wu; Wen-Liang Lo; Yi-Wei Chen
Journal:  J Dent Sci       Date:  2021-01-07       Impact factor: 2.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.